Evidence map›Paper›PMID 35645588›Full record

ReviewSaudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society2022

COVID 19 pandemic challenges and their management: A review of medicines, vaccines, patents and clinical trials with emphasis on psychological health issues.

Sradhanjali Mohapatra, P Ayash Kumar, Uzma Farooq, Pooja Jain, Rahmuddin Khan, Nazia Hassan, Athar Shamim, Mohammad Javed Ansari, Ahmed S Alalaiwe, Mohammed F Aldawsari and 2 more

Open access · hybridAbstract readReview
In one paragraph

Review in Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.2field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 6 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 2 countries.

Sradhanjali MohapatraNanotechnology Lab, School of Pharmaceutics Education and Research (SPER), Jamia Hamdard, New Delhi, India.
P Ayash KumarSun Pharmaceutical Industry Limited, R& D Centre, Gurugram, India.
Uzma FarooqNanotechnology Lab, School of Pharmaceutics Education and Research (SPER), Jamia Hamdard, New Delhi, India.
Pooja JainNanotechnology Lab, School of Pharmaceutics Education and Research (SPER), Jamia Hamdard, New Delhi, India.
Rahmuddin KhanNanotechnology Lab, School of Pharmaceutics Education and Research (SPER), Jamia Hamdard, New Delhi, India.
Nazia HassanNanotechnology Lab, School of Pharmaceutics Education and Research (SPER), Jamia Hamdard, New Delhi, India.
Athar ShamimNanotechnology Lab, School of Pharmaceutics Education and Research (SPER), Jamia Hamdard, New Delhi, India.
Mohammad Javed AnsariDepartment of Pharmaceutics, College of Pharmacy, Prince Sattam Bin Abdulaziz University, Alkharj, Saudi Arabia.
Ahmed S AlalaiweDepartment of Pharmaceutics, College of Pharmacy, Prince Sattam Bin Abdulaziz University, Alkharj, Saudi Arabia.
Mohammed F AldawsariDepartment of Pharmaceutics, College of Pharmacy, Prince Sattam Bin Abdulaziz University, Alkharj, Saudi Arabia.
Mohd Aamir MirzaNanotechnology Lab, School of Pharmaceutics Education and Research (SPER), Jamia Hamdard, New Delhi, India.
Zeenat IqbalNanotechnology Lab, School of Pharmaceutics Education and Research (SPER), Jamia Hamdard, New Delhi, India.
Jamia Hamdard · INPrince Sattam Bin Abdulaziz University · SASun Pharma (India) · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The SARS-CoV-2 (COVID 19) paroxysm is a dominant health exigency that caused significant distress, affecting physical and mental health. Increased mortality, a stressed healthcare system, financial crisis, isolation, and new living and working styles enhanced societal commiseration leading to poor health outcomes. Though people try to maintain good physical health but unfortunately the mental affliction is still ignored. Poor psychological health has emerged as a burgeoning social issue and demands attention. Henceforth, the fundamental objective of this review article is to collate information about COVID-linked physical and psychological agony in diverse population groups with related symptoms and accessible diagnosis techniques. Recent studies have unraveled the fragile mental states of people who have either contracted COVID 19 or had near and dear ones falling prey to it. The impact of the epidemic on the human mind both in short and long-term, with possible risk and preventive factors together with suggested solutions for maintaining good health have also been discussed here. It also enlists the available medications, vaccines and investigational research in the form of patents and clinical trials. This article can be taken as an updated information sheet for COVID 19, accompanied by its management techniques with special emphasis on coping strategies for mental health. Further, it may also assist the policymakers to devise approaches that could enable the public to overcome the pandemic-driven adversity not only in the given situation but also futuristically.

Indexed as

Clinical trialCOVID 19MedicationMental healthPatentsPhysical healthSARS‐CoV‐2Vaccine

Identifiers

PMID35645588
PMCPMC9128298
OpenAlexW4281552477

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.